Is China now ahead of the US in biotech

Is China now ahead of the US in biotech

A recent Boston industry panel and multiple opinion pieces are debating whether China has overtaken the US in biomedical innovation, citing claims that a large share of new American drug candidates now originate in China and that Chinese institutions dominate recent research rankings.

The dominant readingThe US biotech lead is eroding fast and protectionist measures like tariffs and licensing restrictions will only accelerate the decline.

The pushbackOthers argue restricting access to competitively-priced Chinese-originated molecules would only hurt American patients while China still lacks the US ecosystem's depth in translational research.

Anxioushigh volume↑ growingThat day's page →

Is China now ahead of the US in biotech innovation

New that dayReporting now shows the US is actively weighing rules that would preserve companies' ability to strike most pharma licensing deals with China, a notable softening from the earlier restriction-focused framing.

Ongoing argument over whether China has overtaken the US in biomedical innovation continues, fueled by reporting that Chinese out-licensing deal value reached a record high in the first half of 2026 and that nearly half of US drugs licensed from abroad in 2025 originated from Chinese companies.

The dominant readingSome frame the licensing surge as proof China has structurally out-executed the US on speed and cost of drug development.

The pushbackOthers, including biotech executives quoted in policy debates, argue the comparison to semiconductor-style security threats is a category error that risks cutting off a pipeline lifeline US companies need.

Anxioushigh volume↑ growingThat day's page →

Is China now ahead of the US in biotech innovation

New that dayNew reporting on Eli Lilly's fourth China-based drug deal since the start of 2025, an up-to-$100 million upfront InnoCare alliance with up to $3.25 billion in milestones, is being cited as fresh evidence the licensing wave is accelerating rather than plateauing.

The argument over whether China has overtaken the US in biomedical innovation continues, fueled by data showing cross-border pharma licensing between US/European and Chinese companies reached roughly $136 billion in 2025, up from under $5 billion in 2020.

The dominant readingThe explosive growth in Chinese out-licensing volume is being cited as proof that Chinese institutions now originate a disproportionate share of promising new drug candidates that US pharma must license rather than discover in-house.

The pushbackSkeptics argue the licensing-deal volume reflects US pharma's efficient global sourcing strategy rather than a genuine innovation gap, and that US-origin biology and manufacturing scale still lead.

Anxioushigh volume↑ growingThat day's page →